<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[derek lowe Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/derek+lowe.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to derek lowe]]></description>
	<s:counts start="0" returned="20" found="82" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F173555-cholesterol-drug-trials-a-victory-for-abbott-means-a-loss-for-merck%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Over the weekend, the results in a small cardiovascular trial came out that compared Merck's MRK Zetia (ezetimibe/simvastatin) against Abbott's ABT Niaspan (time-release niacin). Niacin's an under-appreciated therapy in the field - it has tolerability problems, mainly irritating and uncomfortable hot flushing, but it really does...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 16 Nov 2009 07:41:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/absolute+software+corp..html"><![CDATA[Absolute Software Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">ABT,ABT,MRK</category>
	</item>
	<item>
		<title><![CDATA[Pfizer's Chemistry Head Count: Lower than Before the Wyeth Merger]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172789-pfizer-s-chemistry-head-count-lower-than-before-the-wyeth-merger%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  A reader who's unfortunately in a position to know the details sends along some numbers on Pfizer's PFE chemistry shakeout. According to his figures, Pfizer (pre-Wyeth merger) had about 900 chemists. The Wyeth deal brought in about 350, but no one expected the merged department to...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 11 Nov 2009 08:39:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pfizer's New Look]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172390-pfizer-s-new-look%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  The company has issued a press release detailing which sites are staying, and which are leaving:    Pfizer PFE will have five main research sites that will serve as central hubs for research activities in BioTherapeutics, PharmaTherapeutics and Vaccines. These sites are: Cambridge, Mass.;...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 10 Nov 2009 12:40:30 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Another Look at Pfizer's Recent Moves]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172473-another-look-at-pfizer-s-recent-moves%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Pharmaconduct.org has another look at Pfizer's PFE announcement Monday, and tries to address some of the many unanswered questions left open by the company's press release. One thing that struck me and many others is that the company talked about "moving a number of functions" from...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 10 Nov 2009 05:31:40 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[J&J's New Acquisition Strategy Makes Sense]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F170065-j-j-s-new-acquisition-strategy-makes-sense%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Johnson & Johnson's JNJ CEO has given an interview to the Financial Times explaining his company's strategy with acquisitions. And right now, that strategy is. ..not to make acquisitions. They see partnerships as making a lot more sense:    &#8220;The cost of developing compounds...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 29 Oct 2009 11:53:41 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Pfizer's People Aren't to Blame]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F168128-pfizer-s-people-aren-t-to-blame%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  I wanted to highlight a comment that showed up recently in the latest Pfizer PFE post:    I would just like to point out that there is often mention of Pfizer as being a poorly productive R&D outfit on this blog, but there is...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 22 Oct 2009 06:41:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pfizer: What It Will Look Like a Year from Now]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167574-pfizer-what-it-will-look-like-a-year-from-now%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  The Wall Street Journal's Health Blog got a chance to ask the higher-ups at Pfizer PFE what their R&D will look like a year from now. Their understandably not too-in-depth answers are here: Decentralized research units, with some functions run company-wide, and this quote: "There are...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 20 Oct 2009 07:41:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Which Pfizer / Wyeth Sites Will Shut Down?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F163691-which-pfizer-wyeth-sites-will-shut-down%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  I have no solid information on this question myself, but Eric Milgram over at Pharmaconduct is trying a wisdom-of-crowds approach. He's got a survey up of which sites people think will close, and it'll be interesting to see how well this matches up with the eventual...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 28 Sep 2009 10:56:48 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Big Pharma's Future Death Spiral?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162227-big-pharma-s-future-death-spiral%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  One of this blog's regular correspondents has just been attending a chemistry outsourcing conference program here, and heard a very interesting talk from Stefan Loren of a Baltimore investment advisory firm, Westwicke Partners. Loren's a product of the Sharpless lab, who went on to Abbott ABT,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 18 Sep 2009 03:29:36 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">MRK,PFE</category>
	</item>
	<item>
		<title><![CDATA[Eli Lilly Braces for Reorganization Moves]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F161661-eli-lilly-braces-for-reorganization-moves%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  The latest re-org announcement is from Eli Lilly LLY. The company is getting braced for the Zyprexa patent expiration (and the possibility that Prasugrel and others won't be able to make up for as much lost revenue as they thought). Their target is a 14% head...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 15 Sep 2009 01:25:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Pfizer Whistle-Blowing: The How and Why]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160167-pfizer-whistle-blowing-the-how-and-why%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Here's more detail on the case that led to Pfizer's PFE 2.3 billion dollar fine/settlement, courtesy of Bloomberg. Here's how things got started, apparently:    Pfizer Inc. sales folks had one tough customer in psychiatrist Stefan Kruszewski. He didn&#8217;t buy their pitch to prescribe...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 06 Sep 2009 04:50:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Sepracor's Suitor Is Hard to Understand]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160165-sepracor-s-suitor-is-hard-to-understand%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Well, I didn't see this one coming. Dainippon Sumitomo has announced that it's buying Sepracor SEPR. My first thought on reading this was "Are they sure they want to do that?"    I say that because the ostensible reason that the Japanese company is...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 06 Sep 2009 04:47:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/sepracor+inc..html"><![CDATA[Sepracor Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SEPR</category>
		<category domain="tickers">SEPR</category>
	</item>
	<item>
		<title><![CDATA[Justice Department Makes 2.3 Billion Dollar Example of Pfizer's Marketing Practices]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159928-justice-department-makes-2-3-billion-dollar-example-of-pfizer-s-marketing-practices%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  No sooner do I write another post about pharma marketing than Pfizer PFE finds itself paying 3.2 billion dollars in fines for doing it improperly. 1.2 billion of that is a criminal penalty, and needless to say, they've set the current record.    The...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 03 Sep 2009 11:59:24 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Forest Lab's Hard Sell of Anti-Depressant Raises Questions]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159719-forest-lab-s-hard-sell-of-anti-depressant-raises-questions%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Forest Labs FRX has done very, very well with Lexapro escitalopram over the years. They're a comparatively small company, and their collaboration with Lundbeck (HLUKY.PK) also a comparatively small company in the antidepressant field has been the biggest event in their history.    Lexapro...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 02 Sep 2009 11:27:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/forest+laboratories+inc..html"><![CDATA[Forest Laboratories Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
		<category domain="tickers">FRX</category>
	</item>
	<item>
		<title><![CDATA[Don't Bury Ariad's Patent Yet]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F158504-don-t-bury-ariad-s-patent-yet%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Ariad's ARIA trek through the legal system has not yet ended! This story has been running for years now - I think the original lawsuit was filed in 2002. Back in the spring, a decision by the Court of Appeals for the Federal Circuit reversed a...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 27 Aug 2009 12:04:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/ariad+pharmaceuticals+inc..html"><![CDATA[ARIAD Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARIA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">ARIA,LLY</category>
	</item>
	<item>
		<title><![CDATA[Eli Lilly's Osteoporosis Drug Stopped in Its Tracks]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F157932-eli-lilly-s-osteoporosis-drug-stopped-in-its-tracks%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Eli Lilly LLY announced some bad news last week when they dropped arzoxifene, a once-promising osteoporosis treatment (and successor to Evista raloxifene, which has been one of the company's big successes).    If this drug had been found ten or fifteen years ago, it...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 24 Aug 2009 07:42:46 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Animal Rights Activists Take Anti-Novartis Protest Too Far]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F155386-animal-rights-activists-take-anti-novartis-protest-too-far%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Novartis NVS has had trouble for years with animal rights activists, and now things are getting nastier than ever:    Novartis CEO Daniel Vasella says the people who burned down his holiday home and defiled his family's graves are not criminals but "terrorists" beyond...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 11 Aug 2009 06:30:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Wyeth Should Be More Forthcoming with Authorship Disclosures]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F154409-wyeth-should-be-more-forthcoming-with-authorship-disclosures%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  As much as I defend the industry I work in, I have to talk about things that we do that I don't think are so defensible. Another one of those has come up thanks to the New York Times and PLoS Medicine, who obtained a pile...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 06 Aug 2009 12:19:32 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Savient's Nasty Gout Surprise]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F153323-savient-s-nasty-gout-surprise%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Well, here's a nasty surprise for you: your new drug gets a 14 to 1 "Yes" vote from an FDA advisory committee, but the agency turns you down, anyway. That's what's just happened to Savient SVNT and their new biologic product for gout, Krystexxa pegloticase. ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 03 Aug 2009 07:18:06 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/savient+pharmaceuticals+inc..html"><![CDATA[Savient Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SVNT</category>
		<category domain="tickers">SVNT</category>
	</item>
	<item>
		<title><![CDATA[Hoping Against Hope for Wyeth / Elan Alzheimer Dug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F150014-hoping-against-hope-for-wyeth-elan-alzheimer-dug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Here's an interesting look at the current state of the Alzheimer's field from Bloomberg. The current big hope is Wyeth WYE (and Elan ELN)'s bapineuzumab, which I last wrote about here. That was after the companies reported what had to be considered less-than-hoped-for efficacy in the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 21 Jul 2009 12:56:02 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
</channel>
</rss>
